BALTIMORE, May 4, 2010 (GLOBE NEWSWIRE) -- Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, has initiated research coverage of Cyplasin Biomedical, Ltd. (OTCBB:CPBM), a biopharmaceutical company focused on the commercialization of life-saving products for use in the multi-billion dollar global hepatitis C virus (HCV) market.
Cyplasin addresses the HCV market with an unusual two-pronged business model. The Company is entering the HCV treatment space as a generic drug provider and based on very positive animal tests for its therapeutic platform licensed from NIH, it plans to submit a Phase I protocol for its own treatment of HCV in 1Q11. Cyplasin is the only company with a VLP (virus-like particles) vaccine under development to prevent and eliminate HCV infection.
In the Goldman Select Research report on the Company, analyst Rob Goldman outlines milestone events that he believes will serve as catalysts for the Company's shares.
"The generics first and clinical trials second model means revenue is in the coming quarters and the huge potential of R&D remains down the road, but with lower risk. Plus, we expect Cyplasin to sign financing agreements in 2Q10 and the commercialization of its generics strategy in 2H10 validate the model and address initial working capital requirements. All of these events should serve as catalysts for the stock."
To view a summary of the report or download the report in its entirety, please visit www.goldmanresearch.com
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces stock market research reports. The Firm produces research via two formats: Goldman Select Research and Goldman Opportunity Research. The Select product reflects the Firm's internally generated stock ideas while the Opportunity product reflects sponsored research reports. While performance is tracked separately, the same coverage criteria are utilized in determining coverage of all stocks in both research formats.
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap research nor it s parent is a registered investment adviser or broker-dealer. To download our research or for more information, visit www.goldmanresearch.com.
About Cyplasin Biomedical, Ltd.: Cyplasin Biomedical Ltd. (OTCBB:CPBM) is a biopharmaceutical company focused on the commercialization of life-saving products targeted for sale in the multi-billion dollar global hepatitis C virus (HCV) market. The Company is engaged in developing and commercializing less expensive and better tolerated anti-viral therapies and a preventive vaccine made from a ground-breaking new vaccine technology known as virus-like particles (VLPs). Cyplasin Biomedical is the only company with a VLP vaccine under development to prevent and eliminate HCV infection. For more information, please visit www.c-pharma.net